CA3225704A1 - Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases - Google Patents

Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases Download PDF

Info

Publication number
CA3225704A1
CA3225704A1 CA3225704A CA3225704A CA3225704A1 CA 3225704 A1 CA3225704 A1 CA 3225704A1 CA 3225704 A CA3225704 A CA 3225704A CA 3225704 A CA3225704 A CA 3225704A CA 3225704 A1 CA3225704 A1 CA 3225704A1
Authority
CA
Canada
Prior art keywords
compound
ona
pharmaceutically acceptable
alkyl
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225704A
Other languages
English (en)
French (fr)
Inventor
Santosh C. Sinha
Sridhar Govinda PRASAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plex Pharmaceuticals Inc
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of CA3225704A1 publication Critical patent/CA3225704A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3225704A 2021-06-28 2022-06-28 Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases Pending CA3225704A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163215818P 2021-06-28 2021-06-28
US63/215,818 2021-06-28
PCT/US2022/035336 WO2023278464A1 (en) 2021-06-28 2022-06-28 Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases

Publications (1)

Publication Number Publication Date
CA3225704A1 true CA3225704A1 (en) 2023-01-05

Family

ID=84692077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225704A Pending CA3225704A1 (en) 2021-06-28 2022-06-28 Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases

Country Status (7)

Country Link
US (1) US20240327439A1 (https=)
EP (1) EP4362923A4 (https=)
JP (1) JP2024524433A (https=)
CN (2) CN116963727A (https=)
CA (1) CA3225704A1 (https=)
MX (1) MX2024000116A (https=)
WO (1) WO2023278464A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
EP4243798A4 (en) * 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID19540A (id) * 1997-01-22 1998-07-23 Hoffmann La Roche Metode pembuatan turunan-turunan benzofenon
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
KR20060013632A (ko) * 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
WO2018036498A1 (en) * 2016-08-24 2018-03-01 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
KR20230021002A (ko) * 2020-06-09 2023-02-13 에이에스엠엘 홀딩 엔.브이. 내장 동축 조명부를 갖는 리소그래피 사전-정렬 이미징 센서
EP4243798A4 (en) * 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES

Also Published As

Publication number Publication date
MX2024000116A (es) 2024-06-19
WO2023278464A1 (en) 2023-01-05
US20240327439A1 (en) 2024-10-03
CN116963727A (zh) 2023-10-27
JP2024524433A (ja) 2024-07-05
EP4362923A4 (en) 2025-03-19
EP4362923A1 (en) 2024-05-08
CN117915900A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
AU2011259997B2 (en) N-acetyl-DL-leucine, neuroprotective and retinoprotective medicament
CA2909160C (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
CA3225704A1 (en) Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases
US9713597B2 (en) Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
IT8149790A1 (it) Un nuovo trattamento della cataratta
CN101151034A (zh) 含有前列腺素F2α衍生物作为有效成分的视网膜神经细胞保护剂
CA3005714A1 (en) Triaryl methane composition, dye composition for ocular membrane dyeing
ES2860767T3 (es) Mirabegrón para el tratamiento de enfermedades retinianas
IT9020968A1 (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
US20220389023A1 (en) Compounds, compositions, and methods for protein degradation
US20250019352A1 (en) Pharmacological agents for treating ophthalmic diseases
BR112012022349B1 (pt) Composto, método para tratar uma doença, e, processo
JP5969872B2 (ja) フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤
EP2762144B1 (en) Combination of hyaluronic acid and flavin adenine dinucleotide for use in inhibiting corneal epithelial cell death
WO2025090994A1 (en) Compositions for treating cataracts and/or presbyopia eye diseases
US3824313A (en) Topical opthalmic composition and methods of use
WO1994003167A1 (fr) Remede contre la cataracte
TWI901889B (zh) 胱胺的用途
EP4302760A1 (en) Aspirin-mimetic antioxidants for treatment of age-related cataract
RU2245138C1 (ru) Способ лечения глазных заболеваний и глазные капли и глазная мазь для его осуществления
WO2011162633A1 (ru) Мягкие катионные митохондриальные разобщители
CN115068466A (zh) 7,4′二羟基-8-甲氧基高异黄烷防治帕金森病的应用
US20260103485A1 (en) Compound based on oxidative stress and anti-amyloid aggregation mechanism, preparation method therefor and use thereof
PL136417B1 (en) Method of obtaining novel /1-benzyl-1h-indazolyloxy-3/acetic salt with lysine
JP2020015707A (ja) 水泡性角膜症治療用医薬組成物

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625